1. Impact of Cognitive Behaviour Therapy Via Mail for Cessation of Benzodiazepine Use: A Series of Case Reports
- Author
-
David J. Kavanagh, Nick Bradizza, Jannette M. Parr, Barbara Stubbs, and Ross McD. Young
- Subjects
Benzodiazepine ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Alternative medicine ,Experimental and Cognitive Psychology ,Muscular tension ,Cognitive behaviour therapy ,Clinical Psychology ,Qualitative feedback ,medicine ,Physical therapy ,Anxiety ,Dose reduction ,medicine.symptom ,Medical prescription ,business ,Clinical psychology - Abstract
Benzodiazepines are widely prescribed to manage sleep disorders, anxiety and muscular tension. While providing short-term relief, continued use induces tolerance and withdrawal, and in older users, increases the risk of falls. However, long-term prescription remains common, and effective interventions are not widely available. This study developed a self-managed cognitive behaviour therapy package for cessation of benzodiazepine use delivered to participants via mail (M-CBT) and trialled its effectiveness as an adjunct to a general practitioner (GP)-managed dose reduction schedule. In the pilot trial, participants were randomly assigned to GP management with immediate or delayed M-CBT. Significant recruitment and engagement problems were experienced, and only three participants were allocated to each condition. After immediate M-CBT, two participants ceased use, while none receiving delayed treatment reduced daily intake by more than 50%. Across the sample, doses at 12 months remained significantly lower than baseline, and qualitative feedback from participants was positive. While M-CBT may have promise, improved engagement of GPs and participants is needed for this approach to substantially impact on community-wide benzodiazepine use.
- Published
- 2013
- Full Text
- View/download PDF